Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kinjal Sanghavi

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
The AAPS Journal|February 28, 2018
Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal AntibodiesChaitali Passey, Satyendra Suryawanshi, Kinjal Sanghavi, et al.
Cancer Chemotherapy and Pharmacology|November 26, 2021
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myelomaTakafumi Ide, Mayu Osawa, Kinjal Sanghavi, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2021
Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posologyKinjal Sanghavi, Pradeep Vuppala, Vijay Ivaturi, et al.
Drug Safety|March 2, 2026
QT Prolongation Risk of Antibody-Drug ConjugatesXu Steven Xu, Kinjal Sanghavi, Summer Feng, et al.
Clinical Pharmacology and Therapeutics|December 20, 2023
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid TumorsYue Zhao, Kinjal Sanghavi, Amit Roy, et al.
Journal of Clinical Pharmacology|September 19, 2017
Clinical Pharmacology Considerations for the Development of Immune Checkpoint InhibitorsJennifer Sheng, Shivani Srivastava, Kinjal Sanghavi, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2018
Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusionAbeer F Alharbi, Robert A Kratzke, Jonathan D'Cunha, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid TumorsKinjal Sanghavi, Jason Zhang, Xiaochen Zhao, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced MalignanciesJason Zhang, Kinjal Sanghavi, Jun Shen, et al.
Springerplus|February 4, 2015
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatmentAnne Blaes, Daniel Duprez, Todd Defor, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The AAPS Journal|February 28, 2018
Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal AntibodiesChaitali Passey, Satyendra Suryawanshi, Kinjal Sanghavi, et al.
Cancer Chemotherapy and Pharmacology|November 26, 2021
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myelomaTakafumi Ide, Mayu Osawa, Kinjal Sanghavi, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2021
Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posologyKinjal Sanghavi, Pradeep Vuppala, Vijay Ivaturi, et al.
Drug Safety|March 2, 2026
QT Prolongation Risk of Antibody-Drug ConjugatesXu Steven Xu, Kinjal Sanghavi, Summer Feng, et al.
Clinical Pharmacology and Therapeutics|December 20, 2023
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid TumorsYue Zhao, Kinjal Sanghavi, Amit Roy, et al.
Journal of Clinical Pharmacology|September 19, 2017
Clinical Pharmacology Considerations for the Development of Immune Checkpoint InhibitorsJennifer Sheng, Shivani Srivastava, Kinjal Sanghavi, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2018
Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusionAbeer F Alharbi, Robert A Kratzke, Jonathan D'Cunha, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid TumorsKinjal Sanghavi, Jason Zhang, Xiaochen Zhao, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced MalignanciesJason Zhang, Kinjal Sanghavi, Jun Shen, et al.
Springerplus|February 4, 2015
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatmentAnne Blaes, Daniel Duprez, Todd Defor, et al.
Pageof 2